|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
This retrospective analysis evaluated the incidence, risk factors, and types of infectious complications (IC) in adults with CD20+ non-Hodgkin lymphoma who received ≥2 cycles of B and either R or ofatumumab.
|
31603363 |
2020 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
The majority of NHLs are of B-cell lineage, for which traditional therapy involves chemotherapy in combination with the anti-CD20 monoclonal antibody rituximab.
|
31385204 |
2020 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
The concept of the Magic Bullet has since been extended to other disease states such as (1) <sup>131</sup>I-meta-iodobenzylguanidine (<sup>131</sup>I-MIBG) to treat malignant and metastatic pheochromocytomas and paragangliomas; (2) <sup>131</sup>I-tositumomab, a radioiodinated anti-CD20 IgG to treat CD20 expressing non-Hodgkins lymphoma.
|
31843064 |
2020 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
B-cell CD20 receptors and Non-Hodgkin lymphoma (NHL) were chosen as the first target.
|
30391799 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
The safety of the next-generation compounds umbralisib, a PI3K-δ inhibitor, plus ublituximab, an anti-CD20 monoclonal antibody (combination referred to as U2), was evaluated in patients with chronic lymphocytic lymphoma (CLL) or non-Hodgkin lymphoma (NHL) in this phase 1/1b study.
|
31558467 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab is an anti-CD20 monoclonal antibody approved in non-Hodgkin lymphoma (NHL).
|
31112622 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, numerous clinical trials of lenalidomide, as single agent, in combination with anti-CD20 antibodies, or in combination with chemoimmunotherapy regimens, have shown promise in aggressive and indolent NHL in both the upfront and relapsed/refractory setting.
|
31302872 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence indicates that the anti-CD20 monoclonal antibody rituximab significantly improves the clinical prognosis of patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.
|
30655772 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Without the need of low molecular weight drug, the hybridisation of morpholino oligonucleotide containing DFMT at NHL cell surface triggers CD20 crosslinking and subsequent apoptosis.
|
30198798 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
|
31772298 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
HBV DNA monitoring-guided preemptive NAT was effective in preventing HBV-related hepatitis during anti-CD20-containing immunochemotherapy in B-cell NHL patients with resolved HBV infection.
|
30341058 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-CD47 drug Hu5F9-G4, also known as 5F9, in combination with the anti-CD20 therapy rituximab, may be a promising treatment for some forms of non-Hodgkin lymphoma because it allows macrophages to recognize and attack cancer cells.
|
30464001 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the therapeutic potential of the next-generation anti-CD37 radioimmunoconjugate <sup>177</sup> Lu-lilotomab satetraxetan (<sup>177</sup> Lu-lilotomab) in combination with the anti-CD20 antibody rituximab for treatment of mice with non-Hodgkin's lymphoma (NHL) xenografts.
|
29993152 |
2018 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
The introduction of anti-CD20 antibody rituximab for the treatment of B-cell NHLs has significantly improved the clinical outcome of these malignant diseases.
|
29624913 |
2018 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-CD20 monoclonal antibodies can be used to image and treat non-Hodgkins lymphoma, though this has not been as commercially successful as initially predicted.
|
29474096 |
2018 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
The treatment effector in our pretargeting system can not only selectively deliver radionucleotides to the target tumor cells but also increase the complement-dependent cytotoxicity of α-CD20 and thus enhance the antitumor effects, as justified by comprehensive in vitro and in vivo studies in mouse NHL xenograft and disseminated models.
|
29361211 |
2018 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, we developed a rituximab (anti-CD20)-modified mTOR inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) for trial of its anti-NHL effect.
|
30198340 |
2018 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found CD20 transcription is negatively regulated by FOXO1 in NHL cell lines and in human lymphoma specimens carrying activating mutations of <i>FOXO1</i>.
|
29721381 |
2018 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab was administrated at 375 mg/m<sup>2</sup> on day 1 for CD20+ NHL.
|
28374163 |
2017 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Facilitating the development of alternative targeted therapeutic strategies is urgently required to improve outcome or circumvent chemotherapy resistance in children, adolescents, and adults with recurrent/refractory de novo mature B-cell (CD20) non-Hodgkin lymphoma, including Burkitt lymphoma (BL).
|
28932644 |
2017 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma.
|
29054987 |
2017 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although discovery of the anti-CD20 antibody rituximab has markedly improved outcomes in B-cell NHL, rituximab resistance remains an important obstacle to successful treatment of these tumors.
|
28137826 |
2017 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting the CD20-positive B-cells with therapeutic monoclonal antibodies (MAbs) has been an effectual strategy in the treatment of hematologic malignancies such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
|
28067179 |
2017 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that NK-92MIhCD16 and NK-92MIhCD64 cells significantly improved cytotoxicity against CD20-positive non-Hodgkin's lymphoma cells in the presence of rituximab.
|
28415754 |
2017 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD20 immunotherapy (rituximab) is widely used to treat NHL, even though the initial effectiveness of rituximab varies widely among patients and typically wanes over time.
|
26888257 |
2016 |